Janux prostate cancer data reveals a lower response rate, impacting its clinical trial progress.
Author: PharmaSignal News Desk
Contingent value rights are increasingly used in biotech deals, bridging price gaps amid market turbulence.
UK drug price deal allows the country to avoid US tariffs by adjusting pricing rules for new medicines.
Belite Stargardt drug shows promising results in a late-stage trial, positioning it for potential regulatory approval.
Protego amyloidosis drug receives $130M funding to develop a new treatment for light chain amyloidosis, aiming to improve patient outcomes.
Novartis job cuts impact Swiss manufacturing, affecting hundreds of employees. Novo’s diabetes drug advances to Phase 3 trials. #Novartis #JobCuts #DiabetesDrug #PharmaSignal
Otsuka secures FDA approval for its first anti-APRIL therapy targeting IgA nephropathy, marking a significant advancement in rare kidney disease treatment.
Contingent value rights are increasingly used in biotech deals to bridge price gaps amid market turbulence.#PharmaSignal #Biotech #MergersAndAcquisitions
UK drug price deal allows the country to avoid US tariffs by adjusting pricing rules for new medicines.
Belite Stargardt drug shows promising results in Phase 3 trial, positioning it for potential market approval.